Market Closed -
Nyse
21:00:00 09/05/2024 BST
|
5-day change
|
1st Jan Change
|
1.25
USD
|
+9.65%
|
|
+7.76%
|
-29.78%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
48.67
|
118.5
|
37.89
|
69.41
|
129.9
|
83.58
|
-
|
Enterprise Value (EV)
1 |
48.67
|
118.5
|
37.89
|
69.41
|
129.9
|
83.58
|
83.58
|
P/E ratio
|
-2.67
x
|
-16.5
x
|
-1.34
x
|
-4.42
x
|
19.8
x
|
5.43
x
|
1.41
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
3.07
x
|
7.3
x
|
0.99
x
|
1.46
x
|
1.98
x
|
1.13
x
|
0.66
x
|
EV / Revenue
|
3.07
x
|
7.3
x
|
0.99
x
|
1.46
x
|
1.98
x
|
1.13
x
|
0.66
x
|
EV / EBITDA
|
-5,348,285
x
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
14,838
|
32,643
|
45,557
|
50,666
|
72,952
|
73,316
|
-
|
Reference price
2 |
3.280
|
3.630
|
0.8317
|
1.370
|
1.780
|
1.140
|
1.140
|
Announcement Date
|
12/03/20
|
30/03/21
|
31/03/22
|
27/02/23
|
14/03/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
15.87
|
16.24
|
38.35
|
47.64
|
65.49
|
74.06
|
127.4
|
EBITDA
|
-9.1
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-10.72
|
2.71
|
-20.46
|
-13.01
|
10.46
|
20.29
|
72.99
|
Operating Margin
|
-67.55%
|
16.69%
|
-53.36%
|
-27.32%
|
15.97%
|
27.39%
|
57.32%
|
Earnings before Tax (EBT)
1 |
-18.28
|
-6.523
|
-27.58
|
-14.4
|
8.566
|
17.69
|
70.39
|
Net income
1 |
-18.28
|
-6.523
|
-27.58
|
-14.93
|
8.312
|
17.69
|
70.39
|
Net margin
|
-115.19%
|
-40.18%
|
-71.92%
|
-31.33%
|
12.69%
|
23.88%
|
55.28%
|
EPS
2 |
-1.230
|
-0.2200
|
-0.6200
|
-0.3100
|
0.0900
|
0.2100
|
0.8100
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/03/20
|
30/03/21
|
31/03/22
|
27/02/23
|
14/03/24
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
12.05
|
8.549
|
-
|
8.753
|
14.18
|
8.617
|
-
|
35.08
|
10.34
|
10.49
|
9.2
|
8.9
|
10.5
|
21.6
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-1.885
|
-5.706
|
-
|
-5.524
|
-3.125
|
-2.495
|
-
|
20.42
|
-1.887
|
-5.615
|
-
|
-
|
-
|
-
|
Operating Margin
|
-15.64%
|
-66.74%
|
-
|
-63.11%
|
-22.03%
|
-28.95%
|
-
|
58.22%
|
-18.24%
|
-53.55%
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-4.199
|
-6.667
|
-
|
-5.334
|
-3.567
|
-3.21
|
-
|
19.65
|
-1.719
|
-6.426
|
-
|
-
|
-
|
-
|
Net income
|
-4.199
|
-6.667
|
-2.286
|
-5.334
|
-3.567
|
-3.74
|
-3.131
|
19.34
|
-1.852
|
-6.044
|
-
|
-
|
-
|
-
|
Net margin
|
-34.83%
|
-77.99%
|
-
|
-60.94%
|
-25.15%
|
-43.4%
|
-
|
55.14%
|
-17.9%
|
-57.64%
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.0900
|
-0.1400
|
-0.0500
|
-0.1100
|
-0.0700
|
-0.0700
|
-0.0500
|
0.2100
|
-0.0300
|
-0.0700
|
-0.0200
|
-0.0200
|
-
|
0.1300
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
15/11/21
|
31/03/22
|
16/05/22
|
15/08/22
|
14/11/22
|
27/02/23
|
04/05/23
|
07/08/23
|
06/11/23
|
14/03/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.63
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
3.95%
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/03/20
|
30/03/21
|
31/03/22
|
27/02/23
|
14/03/24
|
-
|
-
|
Last Close Price
1.14
USD Average target price
13
USD Spread / Average Target +1,040.35% Consensus |
1st Jan change
|
Capi.
|
---|
| -29.78% | 83.58M | | +23.37% | 46.71B | | +48.83% | 41.8B | | -0.94% | 41.52B | | -5.86% | 29.55B | | +11.29% | 25.78B | | -20.92% | 19.26B | | +3.20% | 12.14B | | -2.67% | 12.08B | | +30.23% | 11.98B |
Other Biotechnology & Medical Research
|